Proteins and Peptides

22 Sep 2007 ThromboGenics Completes Enrolment of Patients for the Vitreomacular Traction Trial (MIVI IIT)
22 Sep 2007 Maxygen Announces Hold on MAXY-alpha Development Program
22 Sep 2007 One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
21 Sep 2007 Acceleron Pharma's ACE-011 Increases Bone Mineral Density and Bone Strength in Primate Studies
21 Sep 2007 Novo Nordisk receives approval in the EU for use of NovoRapid(R) in elderly people
20 Sep 2007 Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C(TM))
20 Sep 2007 Teva Provides Update on Edratide for Systemic Lupus Erythematosus
19 Sep 2007 New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
19 Sep 2007 Sinobiomed Updates on Clincial Trial Success for Recombinant Batroxobin (rBat)
19 Sep 2007 Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation
18 Sep 2007 A major pharmaceutical company has taken an exclusive option to BA058, a compound licensed by Ipsen to Radius in 2005
18 Sep 2007 SYGNIS' AX200 shows efficacy in stroke patients
15 Sep 2007 Novartis completes agreement with Bayer Schering related to Betaseron(R) rights and manufacturing
15 Sep 2007 Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events
14 Sep 2007 Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study
14 Sep 2007 FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
13 Sep 2007 Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
12 Sep 2007 Phosphagenics to commence Phase 2 TPM/Insulin cinical trial
12 Sep 2007 Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee
12 Sep 2007 Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11 Sep 2007 Neose Announces Initiation of Phase II Renal Trial of NE-180
11 Sep 2007 Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
11 Sep 2007 Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
11 Sep 2007 First Ever Therapy Targets Optic Nerve Head for Glaucoma
07 Sep 2007 FDA has approved Zealand Pharma's Investigative New Drug application

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up